RxDoctor Payments DataLook up a doctor →

Dipenkumar Modi, MD

Internal Medicine · Detroit, MINPI 1821344656

Payments from drug & device makers

$4,079,154in general payments, 2019–2025

Across 909 payments — averaging $4487.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.2M
  • Regeneron$929K
  • Genmab U.S., Inc.$604K
  • Bristol Myers Squibb$228K
  • National Marrow Donor Program$184K
  • Karyopharm Therapeutics Inc.$175K
  • plus $739K from 23 others
$5,285in research payments, 2019–2025

Across 9 payments — averaging $587.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$4K
  • Eli Lilly$2K

What the payments were for

  • Consulting fees$42,35066%
  • Speaking & faculty fees$16,02525%
  • Travel & lodging$2,7654%
  • Food & beverage$2,8814%
  • Education$680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,079,154 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$82,967
Medicare patients
134
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate17$259,999
Acyclovir56$1,253
Prochlorperazine Maleate17$573
Ondansetron Hcl18$163
Allopurinol17$145
Pantoprazole Sodium12$74
Prednisone18$26

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$5,615$259,99917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →